Vyriad

Series-B
vyriad.com Biotech & Healthcare Rochester, United States
Total Funding $25M
Latest Round $25M Series-B
Last Announced Jan 2, 2026
Investors 5 Backers
Decision Makers Profile Active

About Vyriad

Vyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to patients.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Rochester, United States
Tracked Since Nov 6, 2026

Web & Domain Identity

Official Website vyriad.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile @VyriadMN (42 followers)
LinkedIn Corporate Company Profile

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $25,000,000 · Series-B

    Backed by Harry H. Stine

  2. Capital Raise

    Raised undisclosed · Series-B

    fundraisingfox.com

Investors & Backers

5
Harry H. Stine
Lead
Mayo Clinic
Mirae Asset Capital
Regeneron Ventures
Southeast Minnesota Capital Fund

Funding History

2 Rounds
Series-B equity · Jan 2, 2026

Round backers: Harry H. Stine

Series-B equity · May 18, 2022

Founders & Leadership

3

Kah-Whye Peng

Founder

Work email & phone locked Unlock →

Luke Russell

President

Work email & phone locked Unlock →

Stephen Russell

Founder

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts